This is the authors' abstract. We don't add key points for this paper.
Bimetallic silver-copper nanoparticles (AgCu NPs) exhibit enhanced antibacterial properties compared to their monometallic counterparts; however, their clinical translation is limited by poor stability and biocompatibility. Here, we unveil a bacterial incubation-driven synthesis (bacterial-enabled dynamic nanoreactor) of ultra-small AgCu NPs with dual antimicrobial-antitumor functionality. Remarkably, conventional 15 nm AgCu NPs undergo spontaneous size reduction to 2 nm upon interaction with E. coli or S. aureus , accompanied by a complete loss of surface plasmon resonance (SPR) and formation of protein-capped stable dispersions. Mechanistic studies reveal this bacterially triggered transformation involves Ag + release via oxidative dissolution in saline environments, followed by PVP/PVA and bacterial biomolecule-mediated re-nucleation. The US-AgCu NPs demonstrate synergistic therapeutic advantages: Enhanced antibacterial potency compared to parent NPs; pH-selective cytotoxicity; Reusable antimicrobial performance over multiple cycles with minimal resistance development; Long-term stability. This bio-derived strategy achieves kilogram-scale production of therapeutic NPs via continuous fermentation, addressing critical challenges in nanomaterial manufacturing for combating antimicrobial resistance and malignancies. • Bacteria trigger atomic restructuring of AgCu NPs into 2 nm nanoparticles. • PVP/PVA-protein triple shell enables unprecedented colloidal stability. • 23× enhanced antibacterial potency vs parent nanoparticles (MIC 0,067 ppm). • pH-selective cytotoxicity: tumor IC 50 =0.370 μg/mL (B16-F10), normal cell viability >80 %. • Scalable production via continuous fermentation (kg/batch).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Peng et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: